PDL BioPharma, Inc. (PDLI1)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
John Peter McLaughlin
Employees:
297
932 SOUTHWOOD BLVD, INCLINE VILLAGE, NV 89451
775-832-8500

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

PDL BioPharma, Inc. produces and markets biopharmaceutical products. It focuses on intellectual property asset management, investing in new royalty bearing assets and maximizing the value of its patent portfolio and related assets. The company manages a portfolio of patents and royalty assets, consisting of its Queen et al. patents, license agreements with various biotechnology and pharmaceutical companies, and royalty and other assets acquired. PDL BioPharma was founded by Cary L. Queen and Laurence Jay Korn in 1986 and is headquartered in Incline Village, NV.

Data derived from most recent annual or quarterly report
Market Cap 282.14 Million Shares Outstanding114.227 Million Avg 30-day Volume 4.704 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-0.59
Price to Revenue12.5222 Debt to Equity0.0459 EBITDA-35.695 Million
Price to Book Value0.649 Operating Margin-166.2807 Enterprise Value243.304 Million
Current Ratio6.87 EPS Growth-0.255 Quick Ratio4.993
1 Yr BETA 0.7381 52-week High/Low 0.0 / Profit Margin-229.9493
Operating Cash Flow Growth-172.7074 Altman Z-Score3.4457 Free Cash Flow to Firm 389.146 Million
View SEC Filings from PDLI1 instead.

View recent insider trading info

Funds Holding PDLI1 (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding PDLI1

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2020-12-14:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-12-08:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-11-13:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-10-02:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-09-10:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-09-10:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-09-09:
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-09-01:
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-08-31:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-08-28:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • Proxy

    Prospectus

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    SILVER POINT CAPITAL L.P.

    O'SHEA ROBERT J

    MULE EDWARD A

    • 10% Owner
    23,970,334 2021-02-01 0

    GRYSKA DAVID W

    • Director
    1,387 2020-12-30 0

    PARK WEST ASSET MANAGEMENT LLC

    • 10% Owner
    14,397,212 2020-12-30 0

    MCLAUGHLIN JOHN PETER

    • Director
    200,000 2020-12-21 0

    STONE CHRISTOPHER LEWIS VP, GEN. COUNSEL & SECRETARY

    • Officer
    405,559 2020-12-16 0

    MONNET DOMINIQUE PRESIDENT AND CEO

    • Officer
    734,921 2020-12-16 0

    O'FARRELL ELIZABETH G.

    • Director
    0 2020-11-23 0

    BAZAAR ALAN LEE

    • Director
    10,438 2020-11-18 0

    HERNDAY NATASHA

    • Director
    75,826 2020-08-19 0

    IMBROGNO EDWARD VP FINANCE, CAO AND ACTING CFO

    • Officer
    232,077 2020-02-07 0

    JENE JILL M. VP, BUSINESS DEVELOPMENT

    • Officer
    194,805 2020-01-08 0

    SANDMAN PAUL W

    • Director
    0 2019-06-20 0

    SELICK HAROLD E

    • Director
    0 2019-06-20 0

    SAKS SAMUEL R

    • Director
    0 2019-06-20 0

    YANAI SHLOMO

    • Director
    0 2019-06-20 0

    GARCIA PETER S VICE PRESIDENT, CFO

    • Officer
    0 2019-03-28 0

    LINDELL JODY S

    • Director
    256,174 2018-06-08 0

    EDICK PAUL R

    • Director
    214,563 2018-06-08 0

    PIETZKE STEFFEN VP, FINANCE AND CAO

    • Officer
    160,177 2017-12-15 0

    HART DANNY J JR. VP BUSINESS DEVELOPMENT

    • Officer
    387,236 2017-03-04 0

    IMMUNE RESPONSE BIOPHARMA, INC.

    • SHAREHOLDER
    1 2015-05-17 0

    MONTEZ DAVID CONTROLLER AND CAO

    • Officer
    26,719 2015-01-28 0

    TOMLINSON BRUCE CHIEF FINANCIAL OFFICER

    • Officer
    16,509 2012-06-21 0

    FRANK FRED

    • Director
    33,296 2012-06-05 0

    KRUMEL CAROLINE J VPFINANCE/PRIN.ACCTING OFFICER

    • Officer
    9,384 2012-01-18 0

    LARSON CHRISTINE R VICE PRESIDENT AND CFO

    • Officer
    62,049 2011-05-23 0

    KLEIN JOSEPH III

    • Director
    16,994 2009-11-04 0

    WILSON KAREN J VP OF FINANCE & PAO

    • Officer
    10,494 2009-05-07 0

    GUGGENHIME ANDREW SVP & CHIEF FINANCIAL OFFICER

    • Officer
    No longer subject to file 2008-12-18 0

    MCCAMISH MARK ANTHONY SVP & CMO

    • Officer
    No longer subject to file 2008-12-18 0

    CROSS HERB CORP CONTROLLER/PRIN ACCTG OFF

    • Officer
    5,031 2008-09-15 0

    SARENA FRANCIS WILLARD VP/GEN COUNSEL/SECY

    • Officer
    5,756 2008-09-15 0

    LYONS GARY A

    • Director
    0 2008-08-13 0

    HORA MANINDER VP OF PRODUCT OPERATIONS

    • Officer
    4,657 2008-08-13 0

    MURRAY RICHARD /CA/ EVP & CSO

    • Officer
    70,159 2008-07-21 0

    GOODWIN BRADFORD S CHAIRPERSON OF THE BOARD

    • Officer
    • Director
    0 2008-07-16 0

    KORN LAURENCE JAY

    • Director
    0 2008-05-28 0

    DAWES KAREN A CHAIRPERSON OF THE BOARD

    • Officer
    • Director
    2,250 2008-04-29 0

    GAGE L PATRICK INTERIM CEO

    • Officer
    • Director
    19,555 2008-04-28 0

    SHAH JAISIM SVP, MKTG & BUS. AFFAIRS

    • Officer
    16,125 2008-04-28 0

    SAXE JON S

    • Director
    421,680 2008-04-09 0

    IWANICKI DAVID VP, SALES & SALES OPERATIONS

    • Officer
    0 2008-01-02 0

    MCDADE MARK CEO

    • Officer
    • Director
    46,275 2007-07-20 0

    BRODER SAMUEL

    • Director
    26,500 2007-06-20 0

    SHUMATE CYNTHIA LYNN VP LEGAL AFFRS, SECY & CCO

    • Officer
    0 2007-06-20 0

    TORRES LAURIE C VP, CORPORATE SERVICES

    • Officer
    44,072 2007-04-13 0

    CALCOTT PETER H VP, QUALITY & COMPLIANCE

    • Officer
    1,875 2007-01-05 0

    JUE GEORGE VP OF FINANCE

    • Officer
    64,501 2006-11-08 0

    LINK MAX

    • Director
    49,000 2006-06-14 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    FundVantage Trust- Gotham Enhanced Index Plus Fund PDLI1 -20.0 shares, $-56.4 2020-03-31 N-PORT
    FundVantage Trust- Gotham Index Plus All-Cap Fund PDLI1 -34.0 shares, $-95.88 2020-03-31 N-PORT
    Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund PDLI1 -4500.0 shares, $-11115.0 2022-06-30 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments